About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00450437

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

This study will evaluate the lot to lot consistency, safety and immune response of the Novartis Meningococcal ACWY conjugate vaccine in healthy US adolescents and adults.

Lead sponsor: Novartis Vaccines•40 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Novartis Vaccines

Age

11 - 55 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Healthy subjects who are 11-55 years of age inclusive and who have given appropriate written assent and/or consent

Exclusion Criteria

•Subjects with a previous or suspected disease caused by N. meningitidis
•previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)
•previous or suspected disease caused by N. meningitidis
•Any serious acute, chronic or progressive disease
•Pregnant or breastfeeding

Related studies

Active Not RecruitingPhase 3

A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years

NCT06131554 · Meningococcal Meningitis

Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis

NCT02041663 · Meningococcal Infections, Septic Shock, and more

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults

NCT03798574 · Meningococcal Infections, Neisseria Meningitis Sepsis, and more

COMPLETEDPhase 3

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

NCT02955797 · Meningitis, Meningococcal Meningitis, and more

COMPLETEDPhase 3

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

NCT02842866 · Meningitis, Meningococcal Meningitis, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 28, 2015Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment3,539

Start dateMar 2007

Last updatedJan 28, 2015

Condition

Meningococcal Infections Meningococcal Meningitis

Locations shown

Birmingham, Alabama

Tuscaloosa, Alabama

Fremont, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2015Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions